Adaptive Biotechnologies (ADPT) Revenue by Segment

Breaks down income by business unit, illustrating which areas are most lucrative and where there might be growth opportunities.

MRD has turned into the company’s growth engine—volume-driven revenue, rising ASPs and sequencing efficiency are driving faster, higher‑quality growth and margin expansion, supporting a raised MRD guide (though it includes a one‑time $9M milestone). By contrast Immune Medicine is shrinking and loss-making, with a lone large spike likely a timing/milestone anomaly; Adaptive is increasingly concentrated on MRD scale and reimbursement execution, heightening upside but raising diversification and milestone‑lumpiness risk.